Clinical Trial

Experimental Treatment for Rheumatoid Arthritis

Study Description

Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)

The purpose of this study is to to assess the safety and tolerability of pirfenidone 2403 mg/day for the treatment of RA-associated interstitial lung disease.


Locations Selected Location


Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Pirfenidone

Pirfenidone three times daily (2403 mg) for 52 weeks

Drug - Placebo

Placebo three times daily for 52 weeks

Additional Information

Official Study Title

Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients With Rheumatoid Arthritis Interstitial Lung Disease (TRAIL1)

Clinical Trial ID


ParticipAid ID